Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2023 | CSF biomarker-based models to predict MS outcomes

Several studies on cell cultures and animal models investigate multiple sclerosis (MS) progression. Peter Kosa, PhD, National Institutes of Health, Bethesda, MD, discusses the importance of studies on cerebrospinal fluid (CSF) to better understand the molecular mechanisms associated with MS progression. Many processes have been associated with MS progression, such as inflammation, neurodegeneration, and oxidative stress. Still, Dr Kosa’s work focuses on quantifying those processes and using them as biomarkers to better monitor the disease as well as the efficacy of treatments. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.